Alumis Inc. (ALMS)
NASDAQ: ALMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALMS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $514.09M
- EPS (TTM)
- -$3.53
- Dividend yield
- None
- 52-week range
- 3.94 – 31.35
- Day range
- 3.94 – 4.36
- Volume / Avg
- 1.79M / 2.87M
- Beta
- —
- Shares outstanding
- 129.82M
52-week range
ALMS stock today
On Nov 20, ALMS ended the session at $3.96, shedding $0.37 (8.55%), versus the S&P 500's 3.70% decline. Shares are 87.4% below their 52-week high of $31.35, set on Jul 8, 2026 and 0.6% above the 52-week low of $3.94, near the bottom of the past year's range. ALMS is down 59.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.8%.
Alumis has posted a net loss over the last twelve months (EPS of -$3.53), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Alumis
Company profileAlumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Martin Babler Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 251
- IPO year
- 2024
- Website
- alumis.com
Financial highlights
Full financialsIn fiscal 2025, Alumis generated $24.1 million in revenue. Alumis reported a net loss of $243.3 million, compared with a loss of $294.2 million a year earlier. Operating margin was -1886.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $24.05M | — | — |
| Growth | — | — | — |
| Net income | $-243.32M | $-294.23M | $-154.99M |
| EPS (diluted) | $-2.86 | $-10.38 | $-72.08 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$25.38+540.91%
- Strong buy 1
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.73 vs $-0.73
- Surprise
- 0.00%
ALMS news
All ALMS news- Alumis reports Q3 resultsSeeking Alpha
- Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business UpdatesGlobeNewswire
- Alumis Reports Positive Phase 3 Data With EnvudeucitinibNasdaqALMS, ET
- Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresGlobeNewswire
- 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026NasdaqVNDA, PTGX, ALMS, ORKA
Alumis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZVRAZevra Therapeutics Inc. | 8.76 | -3.42% | $521.26M | vs ALMS |
| WVEWave Life Sciences Inc. | 2.56 | -5.88% | $504.91M | vs ALMS |
| CLYMClimb Bio Inc. | 9.19 | -0.97% | $539.80M | vs ALMS |
| HELPHelus Pharma Inc. | 6.11 | -9.88% | $487.68M | vs ALMS |
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs ALMS |
| AVBPArriVent BioPharma Inc. | 10.52 | -6.57% | $544.13M | vs ALMS |
| ACRSAclaris Therapeutics Inc. | 3.44 | -1.71% | $545.63M | vs ALMS |
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs ALMS |
Indexes, lists and sector
Alumis stock FAQ
What is Alumis's stock price today?
ALMS last traded at $3.96 as of Nov 20, 4:00 PM EST, down 8.55% on the day. Prices are delayed at least 15 minutes.
Who is Alumis's CEO?
Mr. Martin Babler Ph.D. is the chief executive officer of Alumis Inc., which has about 251 employees.
What is the ALMS 52-week high?
The 52-week high for ALMS is $31.35 and the 52-week low is $3.94. The stock is currently 87.4% below its high.